Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease

Autor: Adriana Mercan-Stanciu, Letitia Toma, Elena Laura Iliescu
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Nephrology
Cyclopropanes
Male
Sustained Virologic Response
lcsh:RC870-923
Kidney transplantation
chemistry.chemical_compound
0302 clinical medicine
2-Naphthylamine
Chronic kidney disease
Lupus Erythematosus
Systemic
Anilides
030212 general & internal medicine
Prospective Studies
Sulfonamides
Dasabuvir
Hepatitis C virus
Valine
Middle Aged
Direct-acting antiviral therapy
Cryoglobulinemia
030211 gastroenterology & hepatology
Drug Therapy
Combination
Female
medicine.drug
Research Article
medicine.medical_specialty
Proline
Lactams
Macrocyclic
Antiviral Agents
03 medical and health sciences
Internal medicine
medicine
Humans
Renal Insufficiency
Chronic
Uracil
Ritonavir
business.industry
Hepatitis C
Chronic
medicine.disease
lcsh:Diseases of the genitourinary system. Urology
Ombitasvir
chemistry
Paritaprevir
Liver function
Carbamates
business
Kidney disease
Zdroj: BMC Nephrology, Vol 21, Iss 1, Pp 1-9 (2020)
BMC Nephrology
ISSN: 1471-2369
Popis: Background This is a real-world evidence study that aims to analyze the efficacy, tolerability and safety profile of paritaprevir/ombitasvir/ritonavir and dasabuvir, in patients with renal impairment. Methods We conducted an observational prospective study, on 232 patients with chronic kidney disease, undergoing treatment with paritaprevir/ombitasvir/ritonavir and dasabuvir, for chronic hepatitis C infection - genotype 1b. Renal and liver function were assessed at the beginning of therapy, monthly during treatment and three months after therapy completion. Results All patients achieved sustained virologic response. Common side effects were nausea, fatigue and headache. Close monitoring of tacrolimus blood levels and dose reduction was required in kidney transplant recipients. Conclusions HCV therapy in the setting of renal dysfunction has always been a challenging topic. Direct-acting antivirals have shown promising effects, demonstrating good tolerance and efficacy in patients with HCV infection and renal impairment. Sustained virologic response within our study population was 100%.
Databáze: OpenAIRE
Externí odkaz: